Please contact us using the registration form below if you wish to express interest in potentially acquiring any of Astellas’ R&D programs listed below.
- An Astellas representative will contact you after your registration is received. (Please note that Astellas will determine the selected entity(-ies), if any, for further discussion according to the information submitted through this registration system.)
- An Astellas representative will provide selected entities with the Confidential Disclosure Agreement (CDA) template. Please fill in the necessary information on the CDA template and send it to the Astellas representative.
＜List of divestiture programs＞
Please click on each program name for a summary (non-confidential information).
|Program||Mechanism of Action||Update|
|Bispecific T cell recruiting antibody targeting CD37-expressing cells||Sep. 2022|
|Anti-Fn14 monoclonal antibody||Jun. 2022|
|Cathepsin S inhibitor||Dec. 2021|
|Anti-human Igβ antibody||Dec. 2021|
|Anti-TIGIT monoclonal antibody||Sep. 2021|
Please fill out the form and agree with the submission terms.